Miochol-E (Acetylcholine Chloride)

Acetylcholine chloride, the active ingredient in Miochol‑E, is a direct‑acting cholinergic agonist presented as a sterile ophthalmic solution for intraocular use. It induces contraction of the iris sphincter muscle, producing miosis and facilitating aqueous humor outflow, which is useful in ocular procedures and certain glaucoma emergencies.

GNH USA supplies Miochol‑E as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution.

Miochol‑E is employed in ophthalmic care to produce rapid miosis and improve aqueous humor dynamics. - Intraoperative miosis: facilitates surgical access during cataract and other intraocular procedures. - Acute angle‑closure glaucoma: lowers intraocular pressure by enhancing outflow of aqueous humor. - Diagnostic pupillary testing: assists in evaluating iris function and autonomic innervation.

Administration of Miochol‑E may be associated with ocular and systemic adverse reactions.

Common Side Effects: - Transient blurred vision: temporary reduction in visual clarity after instillation. - Eye pain or discomfort: mild irritation at the application site. - Increased lacrimation: excessive tearing lasting minutes to hours. - Conjunctival hyperemia: redness of the eye due to vasodilation.

Serious or Rare Side Effects: - Systemic hypotension: significant blood pressure drop from systemic absorption. - Bronchospasm: airway constriction, particularly in patients with asthma. - Severe allergic reaction: swelling, rash, or anaphylaxis requiring immediate medical attention.

Prior to using Miochol‑E, clinicians should consider several safety measures to minimize risk. - Assess intraocular pressure: confirm baseline pressure to gauge therapeutic need. - Avoid in uncontrolled asthma: cholinergic stimulation may provoke bronchospasm. - Monitor systemic cholinergic effects: watch for bradycardia or hypotension after dosing. - Use caution with concurrent beta‑blockers: additive cardiac slowing may occur. - Check for hypersensitivity: discontinue if allergic signs develop. - Store at ambient temperature: keep in original container, protect from light and moisture.

Miochol‑E can interact with other medications that influence cholinergic pathways or cardiovascular function.

Major Interactions (Avoid): - Systemic cholinesterase inhibitors (e.g., neostigmine): may amplify ocular and systemic cholinergic effects. - Beta‑blockers (e.g., propranolol): combined use can lead to excessive bradycardia or hypotension. - Anticholinergic agents (e.g., atropine): antagonize the intended miotic action, reducing efficacy.

Moderate Interactions (Monitor Closely): - Other miotic agents (e.g., pilocarpine): additive miosis may increase risk of ocular discomfort. - General anesthetics (e.g., succinylcholine): potential for enhanced cholinergic response. - Systemic antihypertensives (e.g., ACE inhibitors): monitor blood pressure for additive lowering effect.